As our data show that MK2 mediates c-MYC activation, which is an important oncogenic pathway in many cancers, and direct inhibition of c-MYC is challenging56, inhibiting MK2 action on OCT4 is potentially a novel therapeutic target in cancers with high c-MYC expression. The gene discussed is MYC; the disease is cancer.